O
ORIC Pharmaceuticals, Inc. (ORIC)
NMS – Real Time Price. Currency in USD
9.53
+0.07 (0.74%)
At close: Jun 26, 2026, 4:00 PM EDT
9.47
-0.06 (-0.63%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
9.53
+0.07 (0.74%)
At close: Jun 26, 2026, 4:00 PM EDT
9.47
-0.06 (-0.63%)
After-hours: Jun 26, 2026, 7:59 PM EDT
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. Charles L. Sawyers B.A., M.D., Ph.D. | Founder & Member of Scientific Advisory Board |
| Dr. Christian V. Kuhlen Esq., J.D., M.D. | General Counsel |
| Dr. Jacob M. Chacko M.B.A., M.D. | President, CEO & Director |
| Dr. Kevin Brodbeck Ph.D. | Chief Technical Officer |
| Dr. Lori Sickels Friedman Ph.D. | Chief Scientific Officer |
| Dr. Pratik S. Multani M.D., M.S. | Chief Medical Officer |
| Dr. Richard A. Heyman Ph.D. | Founder, Independent Chairman & Member of Scientific Advisory Board |
| Dr. Scott W. Lowe Ph.D. | Founder & Member of Scientific Advisory Board |
| Mr. Daniel Iazzetti | VP & Head of People |
| Mr. Dominic G. Piscitelli CPA, M.B.A. | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-06-22 | 8-K | d103876d8k.htm |
| 2026-05-04 | 8-K | oric-20260504.htm |
| 2026-05-04 | 10-Q | oric-20260331.htm |
| 2026-04-28 | DEFA14A | d938346ddefa14a.htm |
| 2026-04-28 | DEF 14A | d47769ddef14a.htm |
| 2026-04-28 | ARS | d938344dars.pdf |
| 2026-03-31 | 8-K | d133016d8k.htm |
| 2026-02-23 | 8-K | oric-20260223.htm |
| 2026-02-23 | 10-K | oric-20251231.htm |
| 2025-12-08 | 8-K | d46273d8k.htm |